Author - Author

Catheter lock solution, anti-clotting and antimicrobial is one of
the innovations from Dirinco

Citra-Lock™ is recommended in the European Renal Best Practice
Guidelines (ERBP) and the American Society of Diagnostic and
Interventional Nephrology (ASDIN).

• Citra locks have been extensively studied.
• Citra-Lock™ is effective in maintaining catheter patency.

Clinical advantage of Citra-Lock™

• safe
• avoids heparin-associated bleeding
• improves reliability of INR assyas (prothrombin time – time/international normalised ratio)
• safe for heparin induced thrombocytopenia (HIT patients)
• no side effects
• reduction of tPA use
• better outcomes over catheter exchange
• reduces biofilm
• reduction of hospitalisation
• cost efficient

 The Citrate lock is based on tri-sodium citrate and can be safely
used in all catheters!

• Citra-Lock™ 5ml vials 4% – 30% -46,7%
• Citra-Lock™S 3ml (prefilled syringe) 4% – 30% -46,7%

 Citra-Lock™S prefilled syringe
Citra-Lock™ 4%      *Twin-Pack  Art.nr. 24060204
Citra-Lock™ 30%    *Twin-Pack  Art.nr. 24060205
Citra-Lock™ 46,7% *Twin-Pack  Art.nr. 24060206
*2x 2.5ml

Using Citra-Lock 46,7%

• improves overall patency rates
• reduces catheter-related infections
• reduces major bleeding for both tunneled an untunneld Central Venous
• Catheters (CVC)

Anti Microbial
Since the introduction of Citra-Lock (46,7%) to the renal departmant of
St.Bard’s renal unit (Royal London Hospital) has proven record in
managing MRSA.
The number of MRSA infections has fallen from 2,27/1000 patiens catheter
days to 1,36/1000 patiens catheter days.

Citra-Lock intervention provides significant benefit to patiens, provides an
extra 2-3 bed days to the hospital an provides savings of € 145.000,- .

Anti Coagulant
Citra-Lock™ is based on higly concentrated trisodium citrate that prevents
clotting and therefore helps maintaining high flow rates whilst greatly
reducing the need for Urokinase/tPA and otheter replacements.

Reducing Biofilm
Trisodium citrate (TSC) lowers infection rates by reducing biofilm
formation in hemodialysis catheters. The study of Bosma (2009)
demonstrates an in vivo reduction of intraluminal catheter biofilm
formation and bacterial colonizasion with the use of TSC 30% for HD
catheter locking. By this mechanism, prevention of catheter-related
infections by TSC can be largely explained.

Increase Safety & Simplified handling
The Citra-Lock™ vial features a drip free Luer-Slip/Luer-Lock
connector:luer slip lock

• preventing microbial contamination
• protecting against needle stick injuries
• reducing handling steps
• promoting intuitive handing

Citra-Lock™ 46,7% 5ml vial
Boxes contain 20 x 5ml vial
Art.nr. 24060202

Using Citra-Lock 30%

• improves overall patency rates
• reduces catheter-related infections
• reduces major bleeding for both tunneled an untunneld Central Venous
• Catheters (CVC)

Anti Microbial
Since the introduction of Citra-Lock (46,7%) to the renal departmant of
St.Bard’s renal unit (Royal London Hospital) has proven record in
managing MRSA.
The number of MRSA infections has fallen from 2,27/1000 patiens catheter
days to 1,36/1000 patiens catheter days.
Citra-Lock intervention provides significant benefit to patiens, provides an
extra 2-3 bed days to the hospital an provides savings of € 145.000,- .

Anti Coagulant
Citra-Lock is based on higly concentrated trisodium citrate that prevents
clotting and therefore helps maintaining high flow rates whilst greatly
reducing the need for Urokinase/tPA and otheter replacements.

Reducing Biofilm
Trisodium citrate (TSC) lowers infection rates by reducing biofilm
formation in hemodialysis catheters. The study of Bosma (2009)
demonstrates an in vivo reduction of intraluminal catheter biofilm
formation and bacterial colonizasion with the use of TSC 30% for HD

catheter locking. By this mechanism, prevention of catheter-related
infections by TSC can be largely explained.

Increase Safety & Simplified handling
The Citra-Lock vial features a drip free Luer-Slip/Luer-Lock connector:

•  preventing microbial contaminationluer slip lock
•  protecting against needle stick injuries
•  reducing handling steps
•  promoting intuitive handing

Citra-Lock™ 30% 5ml vial
Boxes contain 20 x 5ml vial
Art.nr. 24060203

Citra-Lock 4% is recommended in the European Renal Best Practice
Guidelines (ERBP) and the American Society of Diagnostic and
Interventional Nephrology (ASDIN).

Citra locks have been extensively studied.
4% offers the best benefit/risk ratio.
Citra-Lock is effective in maintaining catheter patency.
Trisodium Citrate 4% (TSC) works as an anti-coagulant and decreases the
incidence of infection.

Clinical advantage of Citra-Lock 4% (compared to heparine)

• safe
• avoids heparin-associated bleeding
• improves reliability of INR assyas (prothrombin time – time/international
  normalised ratio)
• safe for heparin induced thrombocytopenia (HIT patients)
• no side effects
• reduction of tPA use
• better outcomes over catheter exchange
• reduction of hospitalisation
• cost efficient

Increase Safety & Simplified handling

The Citra-Lock vial features a drip free Luer-Slip/Luer-Lock connector

•  preventing microbial contamination
•  protecting against needle stick injuries
•  reducing handling steps
•  promoting intuitive handing
• Citra-Lock™ 4% 5ml vial
• Boxes contain 20 x 5ml vials
• Art. nr. :24060201

Brochure